pharmaphorum

NOVEMBER 21, 2024

Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets

98

98

Fierce Pharma

NOVEMBER 3, 2023

The agency previously gave the generic a tentative approval before some patents expire in 2029. . | The D.C. federal court denied Alvogen's bid to force the FDA to grant full approval to its proposed Xifaxan generic.

FDA 115

FDA 115

STAT

OCTOBER 31, 2023

Later, Amgen reworked old patent applications and, by doing so, succeeded in extending patent protection for the medicine from 2019 until 2029, according to an analysis by the advocacy group. Continue to STAT+ to read the full story…

131

131

European Pharmaceutical Review

FEBRUARY 20, 2024

million by 2029. percent between 2022 and 2029. A report from Data Bridge Market Research has predicted that the upstream bioprocessing market will value $14,256.78 Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85

Process Improvement 98

Process Improvement 98

pharmaphorum

OCTOBER 4, 2021

billion in 2029 across eight major markets – the US, France, Germany, Italy, Spain, the UK, Japan, and China. It has forecast that Tecartus will reach peak sales of $110m in ALL worldwide by 2029. GlobalData predicts the ALL market will grow from $1.46 billion in 2019 to $2.26

FDA 109

FDA 109

Fierce Pharma

AUGUST 30, 2023

After settling a patent case with Vivitrol maker Alkermes, Teva has gained a license to launch its generic version of the opioid dependence and alcohol dependence med years ahead of the drug's pate | Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.

75

75

Outsourcing Pharma

JUNE 27, 2024

The US Food and Drug Administration (FDA) has approved Verona Pharmaâs Ohtuvayre (ensifentrine), marking a significant milestone in the treatment of chronic obstructive pulmonary disease (COPD).

FDA 52

FDA 52

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker.

Immunization 143

Immunization FDA 143

Pharmaceutical Technology

JULY 31, 2023

According to GlobalData, it is projected that the market for hepatitis B treatments will experience a sharp increase over the next six years.

52

52

STAT

JUNE 25, 2024

The company said that it expects to add 1,000 new jobs, and that construction will gradually be finalized between 2027 and 2029. Novo Nordisk said the new facility would expand over 56 acres and add 1.4 million square feet of production space, doubling the combined square footage of the other three facilities in North Carolina.

110

110

Pharmaceutical Technology

SEPTEMBER 22, 2023

According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.

59

59

Pharmaceutical Technology

JUNE 24, 2024

The KRAS inhibitor, Krazati, is expected to generate $1.3bn in global sales in 2029, as per GlobalData’s analysis.

Labelling 52

Labelling FDA 52

Pharmaceutical Commerce

JANUARY 5, 2024

US biosimilars market projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

52

52

European Pharmaceutical Review

FEBRUARY 21, 2024

Research predicts 2029 small molecule oncology market leaders The post EGFR inhibitor could provide major advance in lung cancer appeared first on European Pharmaceutical Review. Results from a Phase III trial in the neoadjuvant setting are expected later in 2024.

Chemotherapy 105

Chemotherapy 105

European Pharmaceutical Review

JUNE 26, 2024

Completion is expected between 2027 and 2029. This is compared to the company’s $3.9 (DKK DKK 26 billion) investment in 2023, not including acquisitions. Initial construction work has begun on the new facility. Haemophilia drug could reduce treated bleeding episodes … The post New US fill finish facility receives $4.1

Pharmaceutical Companies 104

Pharmaceutical Companies Pharmaceutical Companies 104

Pharmaceutical Technology

JUNE 27, 2024

Ohtuvaye is expected to rake in $1.1bn in global sales from the market for COPD patients with moderate to severe exacerbations by 2029.

FDA 52

FDA 52

European Pharmaceutical Review

JANUARY 3, 2024

As a result, this approach could treat diseases addressing previously inaccessible drug targets, the company stated. $2

98

98

European Pharmaceutical Review

MAY 20, 2024

It is anticipated that operations will be ready to commence from 2029. The pharmaceutical firm stated that it is planning to begin the design and construction of the manufacturing facility by the end of 2024.

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

NOVEMBER 10, 2023

The construction projects will be finalised from the end of 2025 through to 2029. Once equipped, the facility is expected to create a total of 800 jobs: 700 jobs in the new API facility and 100 jobs in the new packaging facility.

Packaging 111

Packaging 111

European Pharmaceutical Review

APRIL 19, 2024

Ensuring competitiveness in Europe European Federation of Pharmaceutical Industries and Associations (EFPIA) response EFPIA Director General, Nathalie Moll asserted that conditions must be created to drive R&D in Europe, “supporting investment in high-tech, sustainable manufacturing while maintaining open, global supply chains”.

105

105

Pharma Times

MAY 28, 2024

The MRC BRC and the MDU will use the funding and cutting-edge research to improve public health until March 2029

49

49

STAT

SEPTEMBER 19, 2024

House committee passed a  bill  to renew a program aimed at aiding development of drugs for rare diseases in children, putting it in a better position to be added to government funding legislation , STAT reports. The pediatric rare disease priority review voucher program is set to end on Sept.

Compounding 109

Compounding Compounding Pharmacies Packaging Insurance 109

Pharmaceutical Technology

NOVEMBER 1, 2023

The Amgen biosimilar Wezlana has been approved for all indications and is forecasted to yield $455m in 2029.

FDA 52

FDA 52

Pharmaceutical Technology

OCTOBER 23, 2023

The Remicade biosimilar is forecasted to have sales of $2.3bn by 2029 as a subcutaneous form is approved for the US market.

FDA 52

FDA 52

Pharmaceutical Technology

AUGUST 31, 2023

Daiichi Sankyo and AstraZeneca’s blockbuster anti-cancer drug Enhertu could become a pan-tumour drug, with projected sales of $9.9bn by 2029.

FDA 52

FDA 52

Pharmaceutical Technology

SEPTEMBER 23, 2022

It is expected to expire on 21 January 2029, with paediatric exclusivity lasting until 21 July 2029. It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Merck’s second patent covers the co-formulation of sitagliptin and metformin present in Janumet.

FDA 69

FDA Vaccines 69

European Pharmaceutical Review

FEBRUARY 5, 2024

Research predicts 2029 small molecule oncology market leaders A “big step forward” for biotech innovation In a similar move, legislation to restore immediate R&D expensing was passed in the US House of Representatives on 31 January 2024.

FDA 97

FDA 97

Pharmaceutical Technology

MAY 10, 2023

billion in global sales in 2029, while Truvada estimates amount to $30 million. Truvada has since gone generic, with Teva Pharmaceuticals launching the first FDA-approved Truvada generic in October 2020. According to a consensus forecast from GlobalData’s Pharma Intelligence Centre, Descovy is estimated to yield $1.83

Pharmaceutical Companies 105

Pharmaceutical Companies Pharmaceutical Companies FDA 105

pharmaphorum

NOVEMBER 18, 2022

Its CW-2029 – developed in collaboration with AbbVie – is an investigational, conditionally activated ADC directed towards CD71 and has demonstrated encouraging anti-tumour activity in patients with squamous non-small cell lung cancer (NSCLC).

Immunization 105

Immunization 105

European Pharmaceutical Review

JUNE 12, 2023

The facility is expected to start producing API by early 2029. Novo Nordisk explained that, according to internal calculations, production in the future facility in Hillerød will reduce water consumption by more than 40 percent and energy consumption by more than one third, compared to similar API processes in other facilities.

98

98

European Pharmaceutical Review

JUNE 28, 2023

If commercialisation is successful, obicetrapib is expected to value $619 million in sales by 2029, stated GlobalData. According to GlobalData, the CETP inhibitor obicetrapib is in the pipeline for dyslipidaemia. The treatment is expected to launch in 2028 in the US, EU, and Japan. appeared first on European Pharmaceutical Review.

97

97

pharmaphorum

JANUARY 11, 2021

A US distribution agreement will be extended by three years until 2029 and the partnership is being expanded to include a commitment to pursue new opportunities in sourcing and distribution. The two companies have agreed to strengthen their strategic partnership by extending and expanding their commercial agreements.

84

84

European Pharmaceutical Review

JANUARY 2, 2024

According to the research, the global cell and gene therapy market is predicted to value $80 billion by 2029. The field of oncology is anticipated to hold 44 percent of the market by this year.

Immunization 98

Immunization 98

Pharmaceutical Technology

MAY 12, 2023

GlobalData analyst consensus forecasts project sales to reach $11.5bn by 2029, a 29% compound annual growth rate (CAGR). GlobalData analysts predict the total revenue to be generated from currently marketed Seagen ADCs to be roughly $30bn through 2029. targeting ADC.

Chemotherapy 64

Chemotherapy Compounding 64

pharmaphorum

OCTOBER 26, 2022

Ofev is, however, heading for patent expiry in 2029, and Boehringer is looking to BI 1015550 to maintain the franchise beyond that date, and also to improve the treatment of IPF, which remains incurable. First approved back in 2014, it is still growing strongly, with its 2021 sales of €2.5

Labelling 98

Labelling FDA 98

Pharmaceutical Technology

APRIL 28, 2023

In 2022, US sales of Ozempic contributed to 65% of global sales; this is expected to continue, with the US market forecast to continue capturing the majority of sales, generating $71bn between 2023–2029. It is forecast that Ozempic will sustain its sales growth over the next five years, with an expected annual sales figure of $17bn in 2029.

Compounding 52

Compounding Dosage Labelling FDA 52

Fierce Pharma

NOVEMBER 21, 2024

As he introduced Novartis’ meet-the-management event Thursday in London, CEO Vas Narasimhan hammered home Novartis’ status as a streamlined, “pure-play, innovative medicines” company and the succes | Novartis has adjusted its compound annual growth rate expectation from 5%-plus to 6%-plus through 2029.

Compounding 105

Compounding 105